
    
      The study is a randomized, double-blind, Placebo-controlled, multi-center Phase III study. It
      is planned to enroll 590 patients with previously untreated wild-type RAS metastatic
      colorectal cancer. Subjects are randomized into the QL1203 combined with
      Oxaliplatin/5-fluorouracil/ Leucovorin or Placebo combined with Oxaliplatin/5-fluorouracil/
      Leucovorin treatment group by a ratio of 2:1.
    
  